Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model

Calcilytics are calcium‐sensing receptor (CaSR) antagonists that reduce the sensitivity of the CaSR to extracellular calcium. Calcilytics have the potential to treat autosomal dominant hypocalcemia type 1 (ADH1), which is caused by germline gain‐of‐function CaSR mutations and leads to symptomatic hy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JBMR Plus
Main Authors: Hannan, Fadil M, Gorvin, Caroline M, Babinsky, Valerie N, Olesen, Mie K, Stewart, Michelle, Wells, Sara, Cox, Roger D, Nemeth, Edward F, Thakker, Rajesh V
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574706/
https://ncbi.nlm.nih.gov/pubmed/33103030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10402
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados